Clinical trials: Virologically Controlled
HIV-1 Infection
Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels
Master Protocol: The main goal of this master clinical study is to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) of long-acting oral (LAO) regimens in people with HIV-1 (PWH).
- Trial name
- NCT07841990
- Testing
- B/F/TAF, GS-3242, Lenacapavir
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Gilead Sciences
Gastric Influenza
Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir
In order to prevent the high mortality due to an hypothetic pandemic caused by a newly emerging influenza A virus, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks.Two antivirals are…
- Trial name
- BIVIR (NCT00799760)
- Testing
- oseltamivir + zanamivir
- Where
- France
- Volunteers
- 541 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment…
- Trial name
- NCT06891066
- Testing
- ISL, ULO, BIC/FTC/TAF
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial
This is a Phase II, open-label, roll-over trial to evaluate the long term safety and tolerability of TMC125, administered as part of an individually optimized antiretroviral therapy, in HIV 1 infected subjects.
- Trial name
- NCT00111280
- Testing
- TMC125
- Volunteers
- 48 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1 Infection
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologically suppressed people with HIV (PWH) at Week 24.
- Trial name
- NCT05052996
- Testing
- ISL, LEN, B/F/TAF
- Where
- 44 sites in United States
- Volunteers
- 142 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of the accumulated safety data, in adult participants with human immunodeficiency…
- Trial name
- NCT04564547
- Testing
- Islatravir, Ulonivirine, BIC/FTC/TAF
- Where
- 23 sites in United States, France and 1 more
- Volunteers
- 161 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects
The goal of this study is to evaluate the proportion of subjects both antiretroviral experienced and virologically suppressed on lopinavir/ritonavir (LPV/r)400/100mg twice daily who maintain viral suppression after switching to…
- Trial name
- NCT00388492
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Bellos, Nicholaos C., M.D.
HIV-1-infection
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS-3242 plus Lenacapavir (LEN) versus continuing Biktarvy…
- Trial name
- NCT07645287
- Testing
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet
- Where
- 57 sites in United States, Australia and 2 more
- Volunteers
- 175 people
- Sponsor
- Gilead Sciences
HIV Infection
RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection
This study evaluates efficacy and safety of rilpivirine as substitutive agent for the nucleosidic backbone of HAART in virologic suppressed patients when combined with cobicistat-boosted darunavir.
- Trial name
- PROBE2 (NCT04064632)
- Testing
- Rilpivirine + darunavir/cobicistat
- Where
- Italy
- Volunteers
- 1,609 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
HIV-1-infection
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir…
- Trial name
- ISLEND-1 (NCT06630286)
- Testing
- ISL/LEN, B/F/TAF, PTM B/F/TAF
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 609 people
- Sponsor
- Gilead Sciences
HIV
Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1
The purpose of this study is to evaluate the safety and tolerability of VAC-3S in controlled HIV patients receiving standard of care antiretroviral treatment.
- Trial name
- NCT02390466
- Testing
- VAC-3S
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- InnaVirVax
HIV Infection
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
This study will evaluate the safety and efficacy of a switch to Doravirine/Islatravir (DOR/ISL) (MK-8591A) (a fixed dose combination of doravirine 100 mg and islatravir 0.75 mg) in participants living with human immunodeficiency…
- Trial name
- NCT04223791
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Seropositivity
Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients
Autophagy and apoptosis are natural cellular mechanisms which consist for the first in a recycling and elimination process of potentially toxic cellular waste, and for the second in a process of cellular suicide when it becomes…
- Trial name
- GALIG-CBD (NCT05306249)
- Testing
- CBD LGP 50
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
HIV-1-Infection
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard of care treatment in people with human…
- Trial name
- ISLEND-2 (NCT06630299)
- Testing
- ISL/LEN, Antiretroviral Combinations
- Where
- 100 sites in United States, Argentina and 12 more
- Volunteers
- 600 people
- Sponsor
- Gilead Sciences
Impaired Cognition, Depression/Anxiety
Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects
Despite long-term use in clinical practice, chronic treatment with efavirenz (EFV) has been associated with persistent central nervous system symptoms or mild or even asymptomatic neurocognitive impairment.
- Conditions
- Impaired Cognition, Depression/Anxiety, Poor Quality Sleep, Quality of Life
- Trial name
- SWEAR (NCT02042001)
- Testing
- Immediate switch to TDF/FTC/RPV, Switch to TDF/FTC/RPV after 24 weeks
- Where
- 5 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Azienda Ospedaliera San Gerardo di Monza
HIV Positive
Thinking and Memory Problems in People With HIV
Background: People with human immunodeficiency virus (HIV) can sometimes develop thinking and memory problems. These problems can vary widely, from few symptoms to severe problems with memory and concentration.
- Trial name
- NCT01875588
- Where
- United States
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HIV-1-infection
Improving HIV-1 Control in Africa With Long Acting Antiretrovirals
IMPALA is a randomized, open-label, multicenter, interventional study of 540 virologically suppressed HIV-1 infected adults who have a history of sub-optimal adherence to daily oral ART and/or engagement in HIV care.
- Trial name
- IMPALA (NCT05546242)
- Testing
- Cabotegravir/Rilpivirine, Antiretroviral
- Where
- 7 sites in Kenya, South Africa and 1 more
- Volunteers
- 540 people
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued baseline antiretroviral therapy (ART), through Week 48; and to evaluate the…
- Trial name
- NCT05631093
- Testing
- ART, DOR/ISL
- Where
- 53 sites in United States, Australia and 6 more
- Volunteers
- 553 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1-infection
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus…
- Trial name
- ARTISTRY-1 (NCT05502341)
- Testing
- Bictegravir, Lenacapavir, BIC/LEN FDC
- Where
- 94 sites in United States, Argentina and 13 more
- Volunteers
- 689 people
- Sponsor
- Gilead Sciences
HiV1- Positive
Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy
The purpose of this study is to assess the safety, tolerability, and antivira activity of Epzicom in virologically controlled HIV subjects.
- Trial name
- EPZSwitch (NCT01608269)
- Testing
- Abacavir/Lamivudine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Therapeutic Concepts